C

Cellivery Therapeutics Inc
KOSDAQ:268600

Watchlist Manager
Cellivery Therapeutics Inc
KOSDAQ:268600
Watchlist
Price: 6 680 KRW -29.91% Market Closed
Market Cap: 245B KRW
Have any thoughts about
Cellivery Therapeutics Inc?
Write Note

Cellivery Therapeutics Inc
Cash from Operating Activities

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cellivery Therapeutics Inc
Cash from Operating Activities Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash from Operating Activities CAGR 3Y CAGR 5Y CAGR 10Y
C
Cellivery Therapeutics Inc
KOSDAQ:268600
Cash from Operating Activities
â‚©1.2B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Samsung Biologics Co Ltd
KRX:207940
Cash from Operating Activities
â‚©2.1T
CAGR 3-Years
120%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knotus Co Ltd
KOSDAQ:278650
Cash from Operating Activities
â‚©5.2B
CAGR 3-Years
-23%
CAGR 5-Years
9%
CAGR 10-Years
N/A
S
ST Pharm Co Ltd
KOSDAQ:237690
Cash from Operating Activities
â‚©53.1B
CAGR 3-Years
377%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
F
FutureChem Co Ltd
KOSDAQ:220100
Cash from Operating Activities
-â‚©1.5B
CAGR 3-Years
N/A
CAGR 5-Years
18%
CAGR 10-Years
N/A
L
LegoChem Biosciences Inc
KOSDAQ:141080
Cash from Operating Activities
â‚©46.7B
CAGR 3-Years
N/A
CAGR 5-Years
25%
CAGR 10-Years
N/A
No Stocks Found

Cellivery Therapeutics Inc
Glance View

Market Cap
248.4B KRW
Industry
Life Sciences Tools & Services

Cellivery Therapeutics, Inc. engages in the research and development of medicine and pharmacy. The company is headquartered in Seoul, Seoul. The company went IPO on 2018-11-09. The firm develops biotherapeutics capable of entering cells in vivo through proprietary therapeuticmolecule systemic delivery technology (TSDT). The firm research and develop therapeutic drug candidates such as Parkinson’s disease treatment, pancreatic cancer and solid cancer treatment, bone formation promoter, as well as advanced obesity & type II diabetes mellitus; new drugs for research including DNA recombinase and reprogramming factors (RFs).

Intrinsic Value
1 694.23 KRW
Overvaluation 75%
Intrinsic Value
Price
C

See Also

What is Cellivery Therapeutics Inc's Cash from Operating Activities?
Cash from Operating Activities
1.2B KRW

Based on the financial report for Sep 30, 2024, Cellivery Therapeutics Inc's Cash from Operating Activities amounts to 1.2B KRW.

Back to Top